Royal Philips (PHG) on Monday said it was expanding its partnership with Ibex Medical Analytics, further integrating Ibex's artificial intelligence tools for detecting and diagnosing prostate, breast, and gastric cancer into its IntelliSite Pathology scanners and image management systems.
Philips and Ibex began their partnership in 2021. Philips' IntelliSite Pathology platform received 510(k) clearance from the US Food and Drug Administration in July 2024, while Ibex received 510(k) clearance on Feb. 10 for its Prostate Detect, an in-vitro diagnostic device using AI to generate heatmaps identifying small and often-missed prostatic cancers.
Philips earlier this month also disclosed a collaboration with Amazon (AMZN) Web Services to offer cloud archival services for pathology labs, supporting efficient and secure storage and management of digital pathology data.
The company will be demonstrating its Philips IntelliSite Pathology Solution 6.0 at an industry conference now underway and running through Thursday in Boston, it said.
Price: 25.46, Change: -0.03, Percent Change: -0.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。